Company Overview of Reckitt Benckiser Pharmaceuticals, Inc.
Reckitt Benckiser Pharmaceuticals, Inc. manufactures and distributes pharmaceutical products. The company offers opioid medication under the brand name Suboxone and sublingual tablets under the brand name Subutex. Reckitt Benckiser Pharmaceuticals, Inc. was formerly known as Reckitt & Colman Pharmaceuticals, Inc. The company was incorporated in 1997 and is based in Richmond, Virginia. Reckitt Benckiser Pharmaceuticals, Inc. operates as a subsidiary of Reckitt Benckiser Group plc.
The Fairfax Building
10710 Midlothian Turnpike
Richmond, VA 23235
Founded in 1997
Key Executives for Reckitt Benckiser Pharmaceuticals, Inc.
Compensation as of Fiscal Year 2013.
Reckitt Benckiser Pharmaceuticals, Inc. Key Developments
Reckitt Benckiser Pharmaceuticals, Inc. Submits Citizen Petition to United States Food and Drug Administration for Requesting Action to Mitigate Risk of Pediatric Exposure with Opioid Dependence Treatment
Sep 25 12
Reckitt Benckiser Pharmaceuticals, Inc. issued a Citizen Petition to request the U.S. Food and Drug Administration (FDA) to require all manufacturers of buprenorphine-containing products for the treatment of opioid dependence to implement national public health safeguards involving pediatric exposure educational campaigns and child resistant, unit-dosed packaging to reduce the risk of pediatric exposure. The company proactively notified the U.S. FDA on September 18, 2012 that the company is voluntarily discontinuing the supply of Suboxone Tablets in the United States due to these increasing concerns with pediatric exposure. While the data do not isolate the root cause of these findings, the child resistant, unit-dosed packaging of Suboxone Film may be one of the key contributing factors to the decrease in exposure rates compared to Suboxone Tablets that are distributed in a multi-dose bottle containing 30 tablets, since the active ingredient of both products is the same. Other factors may include Reckitt Benckiser Pharmaceuticals' community and healthcare professional educational initiatives in addition to the company's Risk Evaluation and Mitigation Strategy program.
Reckitt Benckiser Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration (FDA) Approval of Two New Dosage Strengths of Suboxone(R) Sublingual Film (C-III) for Maintenance Treatment of Opioid Dependence
Aug 20 12
Reckitt Benckiser Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) approval of the 4 mg and 12 mg doses of Suboxone(R) (buprenorphine and naloxone) sublingual film. Suboxone(R) sublingual film is indicated for maintenance treatment of opioid dependence, also known as prescription opioid painkiller and heroin addiction, a growing epidemic in the United States. Reckitt Benckiser Pharmaceuticals Inc. developed the 4 mg and 12 mg strengths in an ongoing effort to help mitigate the risk of unintentional multi-dose pediatric exposure, which is a major public health concern associated with medications. Having the individually wrapped, unit-dose packaging of Suboxone(R) sublingual film in more dosage choices provides healthcare professionals with more flexible, customizable treatment options, and may help reduce the risk of children accessing inappropriately stored medication. Suboxone(R) sublingual film is an office-based treatment that allows patients to be discreetly treated for opioid dependence in the privacy of a physician's office. Because Suboxone(R) sublingual film is approved for at-home use, people living with opioid dependence can continue their daily lives while under a physician's care similar to other chronic diseases, such as diabetes, asthma or hypertension. Treatment with Suboxone(R) sublingual film is best delivered in conjunction with counseling and psychosocial support. The new 4 mg and 12 mg dosage strengths of Suboxone(R) sublingual film will be available later 2012. About Suboxone(R) Sublingual Film (C-III): Suboxone(R) sublingual film (C-III) was approved by the FDA on August 30, 2010, and combines buprenorphine and naloxone in a 4:1 ratio of 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg and 12 mg/3 mg dosage formulations, respectively. Suboxone(R) sublingual film's main active ingredient is buprenorphine, a partial opioid agonist that strongly binds to the opioid receptors in the brain and blocks other opioids from attaching. Buprenorphine helps reduce opioid use and increases retention in treatment by managing withdrawal symptoms and reducing cravings. Suboxone(R) sublingual film also includes naloxone, an opioid antagonist, to minimize its attractiveness for deliberate misuse. When Suboxone(R) sublingual film is taken as prescribed -- dissolved under the tongue -- the naloxone has no effect.
Reckitt Benckiser Pharmaceuticals, Inc. Wins $148.19 Million Federal Contract
Mar 22 12
Reckitt Benckiser Pharmaceuticals, Inc. won a $148.19 million federal contract from the U.S. Department of Veterans Affairs' National Acquisition Center, Hines, Ill., for chemicals and chemical products.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|